Trials / Unknown
UnknownNCT01893788
Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Nagoya University · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine which treatment will be more effective to reduce left ventricular mass in hypertensive patients with left ventricular hypertrophy comparing aliskiren and eplerenone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren | Aliskiren: 150 to 300 mg daily for 48 weeks |
| DRUG | Eplerenone | 50 to 100 mg daily for 48 weeks |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2016-03-01
- First posted
- 2013-07-09
- Last updated
- 2013-07-22
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01893788. Inclusion in this directory is not an endorsement.